نتایج جستجو برای: janus kinase 2

تعداد نتایج: 2686970  

2013
Xiaobo Wan Yue Ma Christopher L. McClendon Lily Jun-shen Huang Niu Huang

The Janus Kinase 2 (JAK2) plays essential roles in transmitting signals from multiple cytokine receptors, and constitutive activation of JAK2 results in hematopoietic disorders and oncogenesis. JAK2 kinase activity is negatively regulated by its pseudokinase domain (JH2), where the gain-of-function mutation V617F that causes myeloproliferative neoplasms resides. In the absence of a crystal stru...

2008
Dirk Erdmann Bertrand Allard Jacqueline Bohn Alain De Pover Andreas Floersheimer Patrizia Fontana Marc Gerspacher Jean Christophe Hau Francesco Hofmann Thomas Radimerski Roman Wille Catherine Zimmermann Patrick Chène

The Janus kinase 2 (JAK2) is a drug target in particular because a missense mutation in this gene (V617F) has been identified in various human diseases. We report here the first kinetic study of the human full-length wild type and V617F JAK2 proteins and of their isolated kinase domain. The kinetic parameters of both full-length proteins are similar revealing that the mutation does not affect J...

Journal: :Arteriosclerosis, thrombosis, and vascular biology 2011
Taiga Tamiya Ikko Kashiwagi Reiko Takahashi Hideo Yasukawa Akihiko Yoshimura

Various cytokines are involved in the regulation of the immune system and inflammation. Dysregulation of cytokine signaling can cause a variety of diseases, including allergy, autoimmune diseases, inflammation, and cancer. Most cytokines use the so-called janus kinase/signal transducer and activator of transcription pathway, and this pathway is negatively regulated by suppressors of cytokine si...

Journal: :Ibrain 2022

Alzheimer's disease (AD) is a degenerative brain with complex clinical manifestations and pathogeneses such as abnormal deposition of beta-amyloid protein inflammation caused by the excessive activation microglia. CXC motif chemokine receptor type 4 (CXCR4) G protein-coupled that binds to ligand 12 (CXCL12) activate downstream signaling pathways, Janus kinase/signal transducer activator transcr...

2004
Joseph L. Roberts Andrea Lengi Stephanie M. Brown Min Chen Yong-Jie Zhou John J. O’Shea Rebecca H. Buckley

We found 10 individuals from 7 unrelated families among 170 severe combined immunodeficiency (SCID) patients who exhibited 9 different Janus kinase 3 (JAK3) mutations. These included 3 missense and 2 nonsense mutations, 1 insertion, and 3 deletions. With the exception of 1 individual with persistence of transplacentally transferred maternal lymphocytes, all infants presented with a T B NK pheno...

2014
Sara C. Meyer Ross L. Levine

Janus-activated kinases (JAK) are the mediators of a variety of cytokine signals via their cognate receptors that result in activation of intracellular signaling pathways. Alterations in JAK1, JAK2, JAK3, and TYK2 signaling contribute to different disease states, and dysregulated JAK–STAT signaling is associated with hematologic malignancies, autoimmune disorders, and immune-deficient condition...

2016
Jack W Singer Suliman Al-Fayoumi Haiching Ma Rami S Komrokji Ruben Mesa Srdan Verstovsek

Pacritinib, potent inhibitor of Janus kinase 2 (JAK2), JAK2V617F, and fms-like receptor tyrosine kinase 3, is in Phase III development in myelofibrosis. Among type 1 inhibitors, pacritinib shows a lack of myelosuppression at doses that both inhibit JAK2/signal transducer and activator of transcription 3 pathway and demonstrate clinical efficacy. To elucidate these mechanisms and identify other ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید